Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ATXS Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Astria Therapeutics (ATXS) Financials

Astria Therapeutics logo
Compare
Annual Income Statements for Astria Therapeutics

Annual Income Statements for Astria Therapeutics

This table shows Astria Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -52 -73 -94
Consolidated Net Income / (Loss)		 -52 -73 -94
Net Income / (Loss) Continuing Operations		 -52 -73 -94
Total Pre-Tax Income 		-52 -73 -94
Total Operating Income		 -54 -83 -112
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 54 83 112
Selling, General & Admin Expense		 19 26 34
Research & Development Expense		 34 57 77
Total Other Income / (Expense), net		 1.67 10 17
Interest & Investment Income		 1.72 10 17
Other Income / (Expense), net		 -0.06 -0.06 -0.06
Basic Earnings per Share		 ($3.55) ($2.42) ($1.68)
Weighted Average Basic Shares Outstanding		 14.62M 30.12M 56.16M
Diluted Earnings per Share		 ($3.55) ($2.42) ($1.68)
Weighted Average Diluted Shares Outstanding		 14.62M 30.12M 56.16M
Weighted Average Basic & Diluted Shares Outstanding		 27.99M 54.90M 56.43M

Quarterly Income Statements for Astria Therapeutics

This table shows Astria Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -12 - -11 -13 -18 -31 -20 -24 -25 -26
Consolidated Net Income / (Loss)		 -12 - -11 -13 -18 -31 -20 -24 -25 -26
Net Income / (Loss) Continuing Operations		 -12 - -11 -13 -18 -31 -20 -24 -25 -26
Total Pre-Tax Income 		-12 - -11 -13 -18 -31 -20 -24 -25 -26
Total Operating Income		 -12 - -13 -15 -20 -34 -24 -29 -29 -30
Total Operating Expenses		 12 - 13 15 20 34 24 29 29 30
Selling, General & Admin Expense		 4.69 - 5.46 6.01 6.90 7.33 8.42 8.09 8.50 9.43
Research & Development Expense		 7.70 - 8.03 9.09 13 27 16 21 21 20
Total Other Income / (Expense), net		 0.39 - 2.31 2.54 2.51 2.79 4.22 4.63 4.48 3.97
Interest & Investment Income		 0.44 - 2.32 2.56 2.53 2.80 4.24 4.65 4.52 3.96
Other Income / (Expense), net		 -0.05 - -0.02 -0.02 -0.02 -0.01 -0.02 -0.02 -0.04 0.01
Basic Earnings per Share		 ($0.87) - ($0.40) ($0.45) ($0.63) ($0.94) ($0.38) ($0.43) ($0.42) ($0.45)
Weighted Average Basic Shares Outstanding		 13.74M 14.62M 27.94M 28.02M 28.04M 30.12M 52.29M 56.49M 57.82M 56.16M
Diluted Earnings per Share		 ($0.87) - ($0.40) ($0.45) ($0.63) ($0.94) ($0.38) ($0.43) ($0.42) ($0.45)
Weighted Average Diluted Shares Outstanding		 13.74M 14.62M 27.94M 28.02M 28.04M 30.12M 52.29M 56.49M 57.82M 56.16M
Weighted Average Basic & Diluted Shares Outstanding		 16.83M 27.99M 28.03M - 36.30M 54.90M 54.91M 112.85M 56.43M 56.43M

Annual Cash Flow Statements for Astria Therapeutics

This table details how cash moves in and out of Astria Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -66 155 -116
Net Cash From Operating Activities		 -44 -68 -81
Net Cash From Continuing Operating Activities		 -44 -68 -81
Net Income / (Loss) Continuing Operations		 -52 -73 -94
Consolidated Net Income / (Loss)		 -52 -73 -94
Amortization Expense		 - -0.09 -5.61
Non-Cash Adjustments To Reconcile Net Income		 6.23 6.34 13
Changes in Operating Assets and Liabilities, net		 2.07 -1.80 5.27
Net Cash From Investing Activities		 -167 135 -192
Net Cash From Continuing Investing Activities		 -167 135 -192
Purchase of Property, Plant & Equipment		 -0.09 -0.03 -0.33
Purchase of Investments		 -396 -1,924 -4,245
Sale and/or Maturity of Investments		 229 2,060 4,053
Net Cash From Financing Activities		 145 88 157
Net Cash From Continuing Financing Activities		 145 88 157
Issuance of Debt		 - 28 35
Issuance of Common Equity		 145 59 117
Other Financing Activities, net		 0.08 0.42 4.79

Quarterly Cash Flow Statements for Astria Therapeutics

This table details how cash moves in and out of Astria Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 16 -25 182 -68 -14 56 -3.52 -85 -6.48 -21
Net Cash From Operating Activities		 -10 -11 -13 -11 -14 -30 -19 -17 -28 -17
Net Cash From Continuing Operating Activities		 -10 -11 -13 -11 -14 -30 -19 -17 -28 -17
Net Income / (Loss) Continuing Operations		 -12 -13 -11 -13 -18 -31 -20 -24 -25 -26
Consolidated Net Income / (Loss)		 -12 -13 -11 -13 -18 -31 -20 -24 -25 -26
Amortization Expense		 - - - - - - - - -1.73 -1.38
Non-Cash Adjustments To Reconcile Net Income		 1.26 1.05 1.19 1.37 1.70 2.07 2.08 4.26 3.63 3.41
Changes in Operating Assets and Liabilities, net		 0.49 1.55 -3.26 0.58 1.77 -0.90 -1.25 5.63 -5.33 6.23
Net Cash From Investing Activities		 1.95 -135 195 -58 -0.00 -2.02 -126 -68 6.19 -3.72
Net Cash From Continuing Investing Activities		 1.95 -135 195 -58 -0.00 -2.02 -126 -68 6.19 -3.72
Purchase of Investments		 -53 -179 -96 -207 -914 -708 -1,049 -1,388 -1,059 -749
Sale and/or Maturity of Investments		 55 43 291 149 914 706 923 1,320 1,065 745

Annual Balance Sheets for Astria Therapeutics

This table presents Astria Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 231 255 342
Total Current Assets		 228 251 335
Cash & Equivalents		 21 176 60
Short-Term Investments		 206 71 268
Prepaid Expenses		 1.25 4.41 6.51
Plant, Property, & Equipment, net		 0.00 0.00 0.00
Total Noncurrent Assets		 2.94 3.72 7.72
Other Noncurrent Operating Assets		 2.94 3.72 7.72
Total Liabilities & Shareholders' Equity		 231 255 342
Total Liabilities		 9.42 12 23
Total Current Liabilities		 9.06 12 19
Accounts Payable		 0.79 1.51 4.32
Accrued Expenses		 7.69 9.71 13
Other Current Liabilities		 0.58 0.33 1.38
Total Noncurrent Liabilities		 0.36 0.00 3.97
Other Noncurrent Operating Liabilities		 0.36 0.00 3.97
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 221 243 319
Total Preferred & Common Equity		 221 243 319
Preferred Stock		 96 95 95
Total Common Equity		 125 148 224
Common Stock		 633 728 899
Retained Earnings		 -508 -581 -675
Accumulated Other Comprehensive Income / (Loss)		 -0.08 0.00 0.16

Quarterly Balance Sheets for Astria Therapeutics

This table presents Astria Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 120 218 207 194 379 368 362
Total Current Assets		 118 215 204 191 375 358 352
Cash & Equivalents		 46 202 134 120 172 87 81
Short-Term Investments		 71 11 69 69 198 267 263
Prepaid Expenses		 1.91 2.12 1.46 2.66 4.61 3.19 7.58
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 1.33 2.80 2.64 2.40 4.29 10 9.78
Other Noncurrent Operating Assets		 1.33 2.80 2.64 2.40 4.29 10 9.78
Total Liabilities & Shareholders' Equity		 120 218 207 194 379 368 362
Total Liabilities		 6.95 6.88 6.65 9.38 11 21 20
Total Current Liabilities		 6.44 6.67 6.60 9.38 11 16 16
Accounts Payable		 0.79 0.93 0.83 1.14 0.86 2.34 1.28
Accrued Expenses		 5.07 5.16 5.18 7.76 10 13 13
Other Current Liabilities		 0.58 0.59 0.59 0.49 0.17 1.25 1.38
Total Noncurrent Liabilities		 0.50 0.21 0.05 0.00 0.00 4.54 4.26
Other Noncurrent Operating Liabilities		 0.50 0.21 0.05 0.00 - 4.54 4.26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 113 211 200 184 368 347 342
Total Preferred & Common Equity		 113 211 200 184 368 347 342
Preferred Stock		 96 95 95 95 95 95 95
Total Common Equity		 16 116 105 89 272 252 246
Common Stock		 511 635 636 638 873 876 895
Retained Earnings		 -494 -519 -531 -549 -600 -625 -649
Accumulated Other Comprehensive Income / (Loss)		 -0.22 -0.00 0.00 0.00 -0.01 -0.05 0.33

Annual Metrics And Ratios for Astria Therapeutics

This table displays calculated financial ratios and metrics derived from Astria Therapeutics' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 72.54% -55.30% -40.94%
EBIT Growth		 72.54% -55.14% -34.33%
NOPAT Growth		 72.56% -55.19% -34.36%
Net Income Growth		 73.41% -40.62% -29.32%
EPS Growth		 85.56% 31.83% 30.58%
Operating Cash Flow Growth		 -44.38% -57.23% -18.65%
Free Cash Flow Firm Growth		 74.24% -69.15% -21.20%
Invested Capital Growth		 -63.31% 34.61% -159.78%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -31.78% -0.85%
EBIT Q/Q Growth		 0.00% -31.64% 3.98%
NOPAT Q/Q Growth		 0.00% -31.54% 3.97%
Net Income Q/Q Growth		 0.00% -33.15% 5.78%
EPS Q/Q Growth		 0.00% -24.10% 22.58%
Operating Cash Flow Q/Q Growth		 -11.18% -40.05% 13.69%
Free Cash Flow Firm Q/Q Growth		 0.00% -37.59% 12.50%
Invested Capital Q/Q Growth		 0.00% 21.10% -237.35%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 200.00% 100.00%
Interest Burden Percent		 96.78% 175.45% 84.45%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -30.18% -31.40% -33.52%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -13.24% -18.43% -22.16%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -29.98% -29.52%
Net Operating Profit after Tax (NOPAT)		 -37 -58 -78
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.17% -6.25% -5.63%
Return On Investment Capital (ROIC_SIMPLE)		 - -23.91% -24.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -54 -83 -112
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -83 -117
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.74 1.57 2.24
Price to Tangible Book Value (P/TBV)		 1.74 1.57 2.24
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.02
Leverage Ratio		 1.04 2.09 1.06
Compound Leverage Factor		 1.01 1.83 0.90
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 43.58% 78.42% 29.86%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 56.42% 60.79% 70.14%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 11.16 17.76 10.31
Noncontrolling Interest Sharing Ratio		 56.12% 41.29% 33.90%
Liquidity Ratios		 - - -
Current Ratio		 25.13 21.73 17.49
Quick Ratio		 24.99 21.34 17.15
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -35 -60 -73
Operating Cash Flow to CapEx		 -47,838.46% -273,780.00% -24,988.31%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -5.22 -3.41 -8.87
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.02 1.81 -5.46
Enterprise Value (EV)		 88 80 269
Market Capitalization		 218 231 502
Book Value per Share		 $7.42 $4.07 $3.97
Tangible Book Value per Share		 $7.42 $4.07 $3.97
Total Capital		 221 243 319
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -226 -247 -328
Capital Expenditures (CapEx)		 0.09 0.03 0.33
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.81 -7.14 -13
Debt-free Net Working Capital (DFNWC)		 219 239 316
Net Working Capital (NWC)		 219 239 316
Net Nonoperating Expense (NNE)		 14 15 16
Net Nonoperating Obligations (NNO)		 -226 -247 -328
Total Depreciation and Amortization (D&A)		 0.00 -0.09 -5.61
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($3.55) ($2.42) ($1.68)
Adjusted Weighted Average Basic Shares Outstanding		 14.62M 30.12M 56.16M
Adjusted Diluted Earnings per Share		 ($3.55) ($2.42) ($1.68)
Adjusted Weighted Average Diluted Shares Outstanding		 14.62M 30.12M 56.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.99M 54.90M 56.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -37 -58 -78
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Astria Therapeutics

This table displays calculated financial ratios and metrics derived from Astria Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -57.27% 100.00% 12.15% 0.00% -125.78% 0.00% -157.82% -90.58% -51.95% 9.49%
EBIT Growth		 -57.27% 100.00% 12.15% 0.00% -62.89% 0.00% -157.82% -90.58% -43.43% 13.52%
NOPAT Growth		 -56.82% 100.00% 12.26% 0.00% -126.76% 0.00% -157.96% -90.72% -43.38% 13.47%
Net Income Growth		 -52.42% 0.00% 26.99% 0.00% -47.76% 0.00% -156.24% -92.36% -38.40% 18.41%
EPS Growth		 -42.62% 0.00% 66.10% 0.00% 27.59% 0.00% 10.00% 4.44% 33.33% 52.13%
Operating Cash Flow Growth		 -32.26% 0.00% -5.53% 0.00% -39.12% 0.00% -88.15% -56.98% -96.14% 42.58%
Free Cash Flow Firm Growth		 18.20% 126.22% 28.42% 0.00% -114.22% -1,372.05% -57.45% 0.00% -62.57% 40.73%
Invested Capital Growth		 -174.41% -63.31% 37.12% 0.00% -33.96% 34.61% -10.37% -198.36% 39.24% -159.78%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -8.46% 100.00% 0.00% -23.88% -33.94% -68.89% 29.34% -19.24% -6.79% -0.60%
EBIT Q/Q Growth		 -8.46% 100.00% 0.00% -23.88% -33.94% -137.78% 58.69% -19.24% -0.81% -1.82%
NOPAT Q/Q Growth		 -8.18% 100.00% 0.00% -23.85% -67.99% -69.00% 29.38% -19.27% -0.73% -1.99%
Net Income Q/Q Growth		 -6.64% 0.00% 0.00% -12.32% -41.07% -154.37% 36.56% -42.59% -1.50% -4.45%
EPS Q/Q Growth		 -1.16% 0.00% 0.00% -25.00% -80.00% -49.21% 59.57% -26.32% 2.33% -7.14%
Operating Cash Flow Q/Q Growth		 -1.87% 0.00% 0.00% 38.59% -33.30% -224.15% 73.71% 12.06% -66.55% 37.92%
Free Cash Flow Firm Q/Q Growth		 16.59% 132.03% 0.00% 200.00% 0.00% -90.19% 0.00% 19.27% -45.82% 30.67%
Invested Capital Q/Q Growth		 -20.92% -41.15% 0.00% -59.76% -69.29% 42.20% 36.38% -502.21% 65.53% -237.35%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 0.00% 100.00% 200.00% 100.00% 100.00% 200.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.49% 0.00% 82.82% 166.20% 87.52% 183.65% 82.45% 167.75% 84.45% 86.63%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -39.51% -30.18% 0.00% 0.00% -36.82% -31.40% -56.39% -34.06% -38.03% -33.52%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -8.20% -13.24% 0.00% 0.00% -13.08% -36.87% -37.82% -22.20% -24.25% -22.16%
Return on Equity Simple (ROE_SIMPLE)		 -42.58% 0.00% 0.00% 0.00% -29.68% 0.00% -44.40% -26.86% -29.28% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.67 0.00 -9.45 -11 -14 -24 -17 -20 -20 -21
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.68% 0.00% -1.07% -1.97% -2.33% -6.19% -2.07% -1.44% -1.58% -1.71%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -9.85% - - - -6.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -12 0.00 -14 -15 -20 -34 -24 -29 -29 -30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 0.00 -14 -15 -20 -34 -24 -29 -31 -31
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 7.54 1.74 3.20 2.22 2.35 1.57 5.40 2.04 2.58 2.24
Price to Tangible Book Value (P/TBV)		 7.54 1.74 3.20 2.22 2.35 1.57 5.40 2.04 2.58 2.24
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.02 -2.03 -1.03 -1.02 -1.01 -1.02 -1.01 -1.02
Leverage Ratio		 1.05 1.04 1.04 1.04 1.05 1.05 2.06 2.10 1.06 1.06
Compound Leverage Factor		 1.01 0.00 0.86 0.87 1.85 1.92 1.70 0.88 0.89 0.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 85.40% 43.58% 45.10% 95.13% 103.34% 39.21% 51.84% 54.93% 27.90% 29.86%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 14.60% 56.42% 54.90% 104.87% 96.66% 121.58% 148.16% 145.07% 72.10% 70.14%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.74 11.93 30.03 18.37 10.19 19.02 77.22 13.23 17.45 11.10
Noncontrolling Interest Sharing Ratio		 79.24% 56.12% 59.72% 127.89% 128.95% 41.29% 65.84% 34.82% 36.24% 33.90%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 18.40 25.13 32.29 30.98 40.82 43.45 67.65 21.87 22.38 17.49
Quick Ratio		 18.10 24.99 31.97 61.52 20.12 42.69 33.41 43.34 21.90 17.15
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.32 2.02 -11 0.00 -14 -26 -17 -15 -22 -15
Operating Cash Flow to CapEx		 -17,670.69% 0.00% -265,060.00% 0.00% -712,900.00% -377,975.00% 0.00% -5,505.25% -139,825.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -3.70 -5.22 -1.97 -2.56 -4.33 -3.41 -2.17 -7.63 -2.63 -8.87
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.35 -2.02 1.16 0.00 -0.63 1.81 -0.20 -5.07 1.70 -5.46
Enterprise Value (EV)		 104 88 254 126 116 80 461 255 388 269
Market Capitalization		 124 218 372 233 209 231 736 514 637 502
Book Value per Share		 $1.27 $7.42 $4.15 $3.75 $3.18 $4.07 $5.21 $4.58 $4.37 $3.97
Tangible Book Value per Share		 $1.27 $7.42 $4.15 $3.75 $3.18 $4.07 $5.21 $4.58 $4.37 $3.97
Total Capital		 113 221 211 200 184 243 368 347 342 319
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -117 -226 -213 -203 -189 -247 -370 -355 -344 -328
Capital Expenditures (CapEx)		 0.06 0.00 0.01 0.00 0.00 0.02 0.00 0.31 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.53 -7.81 -4.56 -5.14 -6.72 -7.14 -6.46 -13 -8.14 -13
Debt-free Net Working Capital (DFNWC)		 112 219 209 198 182 239 363 342 336 316
Net Working Capital (NWC)		 112 219 209 198 182 239 363 342 336 316
Net Nonoperating Expense (NNE)		 3.33 0.00 1.74 1.99 3.56 7.47 3.02 4.01 4.22 4.91
Net Nonoperating Obligations (NNO)		 -117 -226 -213 -203 -189 -247 -370 -355 -344 -328
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.73 -1.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.87) $0.00 ($0.40) ($0.45) ($0.63) ($0.94) ($0.38) ($0.43) ($0.42) ($0.45)
Adjusted Weighted Average Basic Shares Outstanding		 13.74M 14.62M 27.94M 28.02M 28.04M 30.12M 52.29M 56.49M 57.82M 56.16M
Adjusted Diluted Earnings per Share		 ($0.87) $0.00 ($0.40) ($0.45) ($0.63) ($0.94) ($0.38) ($0.43) ($0.42) ($0.45)
Adjusted Weighted Average Diluted Shares Outstanding		 13.74M 14.62M 27.94M 28.02M 28.04M 30.12M 52.29M 56.49M 57.82M 56.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 16.83M 27.99M 28.03M 28.04M 36.30M 54.90M 54.91M 112.85M 56.43M 56.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.67 0.00 -9.45 -11 -14 -24 -17 -20 -20 -21
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Astria Therapeutics, Inc. (ATXS) quarterly financials over the last four years, focusing on cash flow, profitability, and balance sheet trends. Items are ordered with positives first, then neutral, then negatives.

  • Q3 2024 cash inflows from investing activities: Sale and/or maturity of investments totaling $1,065,000,000.
  • Q4 2024 cash inflows from investing activities: Sale and/or maturity of investments totaling $745,000,000.
  • Q1 2024 financing activity: Net cash from financing activities totaling about $141,807,000, supporting liquidity.
  • Q4 2023 financing activity: Net cash from financing activities totaling about $181,776,000, contributing to cash reserves.
  • Q3 2024 Interest & Investment Income contributed about $4.52 million in non-operating income.
  • Q4 2024 Interest & Investment Income contributed about $3.96 million in non-operating income.
  • Total revenue across the four quarters shown is zero, indicating no product revenue yet.
  • Total assets show a substantial year‑over‑year buildup (roughly $194M at end of 2023 to about $362–379M in 2024), reflecting higher cash and investment balances.
  • Net income attributable to common shareholders was negative in recent quarters: about -$25.63 million in Q4 2024 and -$24.53 million in Q3 2024.
  • Operating cash flow from continuing operations has been negative in every quarter shown (Q1 2024: -$19.09M; Q2 2024: -$16.79M; Q3 2024: -$27.97M; Q4 2024: -$17.36M), indicating ongoing cash burn from operations.
  • Large investments purchases in 2024: Purchase of Investments of about -$1.388 billion in Q2 2024 and about -$1.059 billion in Q3 2024 (significant cash outflows for investments).
05/06/26 09:31 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Astria Therapeutics' Financials

When does Astria Therapeutics' financial year end?

According to the most recent income statement we have on file, Astria Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Astria Therapeutics' net income changed over the last 2 years?

Astria Therapeutics' net income appears to be on an upward trend, with a most recent value of -$94.26 million in 2024, rising from -$51.83 million in 2022. The previous period was -$72.89 million in 2023. Find out what analysts predict for Astria Therapeutics in the coming months.

What is Astria Therapeutics' operating income?
Astria Therapeutics' total operating income in 2024 was -$111.56 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $111.56 million
How has Astria Therapeutics' revenue changed over the last 2 years?

Over the last 2 years, Astria Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Astria Therapeutics have?

Astria Therapeutics' total liabilities were at $23.10 million at the end of 2024, a 100.0% increase from 2023, and a 145.3% increase since 2022.

How much cash does Astria Therapeutics have?

In the past 2 years, Astria Therapeutics' cash and equivalents has ranged from $20.53 million in 2022 to $175.53 million in 2023, and is currently $59.82 million as of their latest financial filing in 2024.

How has Astria Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Astria Therapeutics' book value per share changed from 7.42 in 2022 to 3.97 in 2024, a change of -46.5%.


Related Companies

Financial statements for NASDAQ:ATXS last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
The media's calling it "the biggest IPO in Wall Street history." But I'm not buying it. Institutions got into ...
Decentralized Masters | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
A U.S. Resource Gap Is a National Issue - and Opportunity
America still does not domestically produce one mineral tied to batteries, energy storage, and national defens...
i2i Marketing Group, LLC | Sponsoredtc pixel